Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point
On Air
Feedback
Low Graphics
Help

Thursday, October 29, 1998 Published at 22:46 GMT


Health

Holiday bug vaccine on trial

Holidaymakers often suffer diarrhoea

Early trials have begun on a drug that could make holiday stomach bugs a thing of the past.

The bacteria that cause the problem are enterotoxigenic E. coli (ETEC). There are many forms of E. coli and most of them are harmless to humans.

However, when people travel abroad, they are exposed to unfamiliar forms of ETEC. This exposure can cause severe diarrhoea.

The new vaccine is produced from a form of ETEC that has been genetically modified so that it will not cause diarrhoea in humans.

Researchers at the Cambridge-based company Peptide Therapeutics hope that when holidaymakers drink the medicine, known as Oral ETEC Vaccine, their bodies will develop immunity to the bacteria.

They announced on Thursday that they have gained approval from American regulators to test the drug on human volunteers.

Side-effects

They have started tests on 30 people in America to see whether the vaccine is safe or whether it causes unwanted side-effects.


[ image: Unfamiliar climes bring unfamiliar bacteria]
Unfamiliar climes bring unfamiliar bacteria
About 50% of travellers are thought to develop stomach bugs abroad. Diarrhoea can cause dehydration, and if left untreated can lead to death.

Previously, treatments were only taken after symptoms had made themselves felt.

A successful vaccine would prevent the symptoms developing at all.

The researchers hope that one dose, taken before going abroad, would keep illness at bay.

However, as part of the trials they will look into whether or not booster doses would be needed on longer trips.

Further trials

Scientists believe that five or six particular strains of ETEC are responsible for causing travellers' diarrhoea.

The trial announced on Thursday is a phase one trial, the earliest stage of testing on humans. It will look at a vaccine for one strain, and further phase one trials will look at other strains.

Eventually the researchers will produce a vaccine that guards against all the types of ETEC connected with travellers' diarrhoea.

Gordon Cameron, finance manager for Peptide Therapeutics, said it would be some time before a complete vaccine could go on sale to the public

He said the earliest it would get onto the market would be 2003.

However, the financial rewards for the company and the benefits for travellers will be huge if the vaccine proves to be successful.

It is estimated the overall vaccine market for travellers will exceed £2bn by the end of this decade.

Dr John Brown, chief executive of the company, said: "The potential for this product is enormous and we look forward to reporting continued progress on this and other products over the next few months."



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

03 Aug 98†|†Health
Diphtheria risk 'extremely unlikely'

02 Aug 98†|†Health
Thousands risk diphtheria in jab scare

30 Jun 98†|†Latest News
Salmonella hits British holidaymakers





Internet Links


Peptide Therapeutics

World Health Organisation International Travel and Health

Tips to Avoid Travellers' Diarrhoea


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99